212 related articles for article (PubMed ID: 6189605)
1. Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-phosphate in mice and dogs.
Noker PE; Duncan GF; El Dareer SM; Hill DL
Cancer Treat Rep; 1983 May; 67(5):445-56. PubMed ID: 6189605
[TBL] [Abstract][Full Text] [Related]
2. Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine in mice, dogs, and monkeys.
El Dareer SM; Struck RF; Tillery KF; Rose LM; Brockman RW; Montgomery JA; Hill DL
Drug Metab Dispos; 1980; 8(2):60-3. PubMed ID: 6103788
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-beta-D-arabinofuranosyl-2-fluoroadenine monophosphate (F-araAMP) in P388 murine leukemia-bearing mice.
Avramis VI
Cancer Invest; 1989; 7(2):129-37. PubMed ID: 2477118
[TBL] [Abstract][Full Text] [Related]
4. Physiological disposition of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in humans.
Kreis W; Gordon CS; DeJager R; Krakoff IH
Cancer Res; 1975 Sep; 35(9):2453-60. PubMed ID: 1149046
[TBL] [Abstract][Full Text] [Related]
5. Disposition of indicine N-oxide in mice and monkeys.
El Dareer SM; Tillery KF; Lloyd HH; Hill DL
Cancer Treat Rep; 1982 Jan; 66(1):183-6. PubMed ID: 7053256
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and metabolism studies of two novel 1-deaza-7,8-dihydropteridines in mice.
Noker PE; Hill DL; Kalin JR; Temple CG; Montgomery JA
Drug Metab Dispos; 1985; 13(6):677-81. PubMed ID: 2867870
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of 9-beta-D-arabinosyl-2-fluoroadenine-5'-phosphate by mice bearing P388 leukemia.
Avramis VI; Plunkett W
Cancer Drug Deliv; 1983; 1(1):1-10. PubMed ID: 6085754
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Malspeis L; Grever MR; Staubus AE; Young D
Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279
[TBL] [Abstract][Full Text] [Related]
9. Disposition of thymidine administered as large doses to rats and mice.
Hill DL; Noker PE; Duncan GF; El Dareer SM
Cancer Treat Rep; 1981; 65(5-6):495-9. PubMed ID: 7237470
[TBL] [Abstract][Full Text] [Related]
10. Disposition of 5-methyltetrahydrohomofolate in mice, dogs, and monkeys.
El Dareer SM; Tillery KF; Hill DL
Cancer Treat Rep; 1979 Feb; 63(2):201-7. PubMed ID: 109197
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of para-Chloroaniline Hydrochloride (CAS No. 20265-96-7) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1989 Jul; 351():1-256. PubMed ID: 12704433
[TBL] [Abstract][Full Text] [Related]
12. Plasma and tissue levels of furosemide in dogs and monkeys following single and multiple oral doses.
Yakatan GJ; Maness DD; Scholler J; Johnston JT; Novick WJ; Doluisio JT
Res Commun Chem Pathol Pharmacol; 1979 Jun; 24(3):465-82. PubMed ID: 109903
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388.
Avramis VI; Plunkett W
Cancer Res; 1982 Jul; 42(7):2587-91. PubMed ID: 7083151
[TBL] [Abstract][Full Text] [Related]
14. Distribution and metabolism of prednisone in mice, dogs, and monkeys.
El Dareer SM; Struck RF; White VM; Mellett LB; Hill DL
Cancer Treat Rep; 1977 Oct; 61(7):1279-89. PubMed ID: 412589
[TBL] [Abstract][Full Text] [Related]
15. Identification of metabolites of 9-beta-D-arabinofuranosyl-2-fluoroadenine, an antitumor and antiviral agent.
Struck RF; Shortnacy AT; Kirk MC; Thorpe MC; Brockman RW; Hill DL; El Dareer SM; Montgomery JA
Biochem Pharmacol; 1982 Jun; 31(11):1975-8. PubMed ID: 7115418
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase.
Parker WB; Allan PW; Hassan AE; Secrist JA; Sorscher EJ; Waud WR
Cancer Gene Ther; 2003 Jan; 10(1):23-9. PubMed ID: 12489025
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
18. Disposition and metabolism of carbovir in mice dosed intravenously or orally.
el Dareer SM; Tillery KF; Rose LM; Struck RF; Hill DL
Drug Metab Dispos; 1990; 18(6):842-5. PubMed ID: 1981526
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
[TBL] [Abstract][Full Text] [Related]
20. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
